Law360 reports the European patent court could limit the use of divisional patents in a fight involving Novo Nordisk and Ozempic.
Recap by typeshit. Full story at Law360.
Even genuine pens with foreign prescriptions are seized. Lawmakers and a regulatory official now want a review, as Mounjaro costs over three times more in Korea than Japan.
Novo had asked the court to halt Lilly advertising it objected to. The judge ruled against the request on October 26, Reuters reports.
The think tank argues regulated compounding beats 'research use only' sellers, noting an FDA panel voted to add six peptides despite staff advising against all seven.
Judge Zahid Quraishi found Novo failed to show irreparable harm, so Lilly's superiority ads stay up while the false advertising suit continues.
An overview of how GLP-1 pills are used in diabetes care and how well they work. Little detail beyond the headline was available.
Researchers found remission was far more likely after bariatric surgery than with intensive medical and lifestyle care over the long run.
Loading…